Ovarian Adenocarcinoma
11
1
3
3
Key Insights
Highlights
Success Rate
43% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
36.4%
4 terminated out of 11 trials
42.9%
-43.6% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors
CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma